MetaCap

Optimi Health (OPTH) vs Radiopharm Theranostics (RADX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $8.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OPTH-75.16%RADX-86.24%
+7%-42%-91%
May 20, 20261 yearNov 20, 2026
OPTH-74.19%RADX-86.38%
+6%-42%-91%
May 18, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OPTH versus RADX key metrics
MetricOPTHRADX
Share price$1.51$0.6304
Market cap$8.65M$9.90M
1-day change-13.71%-9.71%
YTD return—-87.92%
1-year return—-86.15%
EPS (TTM)$-1.56$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.63M
Revenue growth (YoY)—+1114.27%
Net income (latest FY)—$-38.34M
Gross margin—1.08%
Operating margin—-1050.63%
Net margin—-1055.27%
52-week high$6.40$16.25
52-week low$1.51$0.63
Distance from 52-week high-76.41%-96.12%
Analyst consensus—strong_buy
Avg. price target upside—+2595.11%
Average volume43.55K55.23K
Shares outstanding5.73M15.70M
Employees—14
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Optimi Health

OPTH stock →

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations

About Radiopharm Theranostics

RADX stock →

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

OPTH vs RADX FAQ

Which is bigger, Optimi Health or Radiopharm Theranostics?

Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $8.65M for Optimi Health (OPTH).

Are Optimi Health and Radiopharm Theranostics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons